We are joined by Niels Reinmuth (Asklepios Kliniken Munich-Gauting) at ESMO 2019 to discuss his presentation on PD-L1 expression in primary tumours versus metastatic samples in the phase III MYSTIC study in first-line metastatic NSCLC.
Questions
1. Could you tell us a little about the MYSTIC study and its major findings? (00:07)
2. What was the relationship between programmed death-ligand 1 (PD-L1) expression and the efficacy of durvalumab? (00:50)
3. How did the expression of PD-L1 differ between primary tumour and metastatic samples? (01:30)
4. What are the implications of these findings for clinical practice? (01:51)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Neils Reinmuth disclosed a relevant relationship with AstraZeneca.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
